Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol

American Journal of Health-System Pharmacy

Volumn 58, Issue 18, 2001, Pages 1734-1739

  Ito, M K ^a   Lin, J C ^a   Morreale, A P ^a   Marcus, D B ^a   Shabetai, R ^a   Dresselhaus, T R ^a   Henry, R R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antilipemic agents; Costs; Economics; Hyperlipidemia; Pravastatin; Simvastatin; Substitution

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DYSLIPIDEMIA; EDUCATION PROGRAM; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL;

EID: 0035884206     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.18.1734     Document Type: Article

References (29)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID atherosclerosis substudy
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAP/TexCAPS
6. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
7. Treatment success in patient subgroups in the lipid treatment assessment project (L-TAP)
8. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs medical center
9. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
10. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
11. Converting patients from lovastatin to fluvastatin
12. Replacing lovastatin with pravastatin: Effects on serum lipids and costs
13. Rationale, design, and baseline results of the pravastatin-to-simvastatin conversion lipid optimization program (PSCOP)
14. Determination of glucose in blood using glucose oxidase with an alternate oxygen acceptor
15. ++ precipitation procedure for quantitation of high density lipoprotein cholesterol
16. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge
17. An updated coronary risk profile. A statement for health professionals
18. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings
19. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
20. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to findings of the Framingham study
21. Representativeness of the Framingham risk model for coronary heart disease mortality: A comparison with a national cohort study
22. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease related events
23. The effects of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
24. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
25. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia
26. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
27. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic
28. Physician extenders for cost-effective management of hypercholesterolemia
29. Improving the quality of outcomes research involving pharmaceutical services